At the end of 2019, the first successes in the treatment of beta-thalassemia patients with the CRISPR/Cas9 procedure at the University Hospital Regensburg (UKR) were achieved. In a further study, gene therapy in the field of sickle cell diseases was investigated, and here, too, the physicians can report initial successes. For more information